Consumer behavior in probiotic consumption

MicrobiomePost carried out a research analysis in collaboration with Analytics Arts to find out more about the motivations and frequency of probiotic consumption and the level of consumer information.

Diet switching quickly impacts the gut microbiota and immune system

Two weeks of dietary intervention are sufficient to influence host immunity, metabolism and gut microbiota composition.

MaaT Pharma demonstrates significant survival benefits with MaaT013 in Acute Graft-Versus-Host Disease

These findings underscore MaaT013's potential as a third-line treatment option, where traditional treatments often fall short.

Gut microbes may influence susceptibility to respiratory infections 

The results of a recent study reveal that the severity of respiratory infections depends at least in part on a complex interplay between the gut microbiota and the immune system.

Revolutionizing skin health: advanced probiotic-oil suspension to transform microbial balance in seborrheic dermatitis

Researchers at the San Gallicano Dermatological Institute in Rome, Italy, conducted an open-label exploratory trial to assess the therapeutic potential of EUTOPLAC, a topical probiotic containing Lactobacillus crispatus P 17631…

The role of the microbiome in chronic lung disease

Aran Singanayagam, research group leader at Imperial College London (UK), examined how disturbances in the airway microbiome are instrumental in the development of chronic lung diseases.

Gut microbes may help ease gastrointestinal damage associated with aspirin use

The results of a recent study shed light on the effects of aspirin use on the gut microbiota. The findings may also inform therapies for aspirin-mediated gastrointestinal damage.

Breast milk establishes a ‘protective’ gut microbiota, promoting infant health

The findings of a recent study shed light on the role of complement proteins in breast milk and provide a mechanism through which breastfeeding may provide protection from certain bacterial…

EnteroBiotix embarks on groundbreaking phase 2 trial for innovative IBS treatment

Launching a new frontier in IBS management: the 'TrIuMPH' trial sets the stage with EBX-102-02, a pioneer in microbiome-based therapy.

Challenges in clinical trial execution for Live Biotherapeutics

An exclusive interview with Daniel Brownell, Senior Director of Research & Development at AOBiome Therapeutics, whose core technology is ammonia oxidizing bacteria, formulated as a topical suspension of bacteria applied…

Subscribe to MicrobiomePost newsletter

Take full advantage of MicrobiomePost‘s features.

Scroll to Top